DexCom (DXCM) just received FDA clearance for Smart Basal, a new device designed to help adults with Type 2 diabetes optimize their insulin dosing using personalized, real-time sensor data. This ...

The average one-year price target for DexCom (NasdaqGS:DXCM) has been revised to $88.30 / share. This is a decrease of 13.54% ...

In honor of National Diabetes Awareness Month, DAV (Disabled American Veterans) announced today a new strategic partnership ...

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an ...

Rising costs and complex care make diabetes a daily challenge. Local patient and pharmacy expert share strategies, struggles, ...

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who ...

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who ...

What a brutal six months it’s been for DexCom. The stock has dropped 32.6% and now trades at $58.63, rattling many ...

The DJS Law Group  reminds investors of a class action lawsuit against  DexCom, Inc. ("DexCom " or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule ...

Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plai ...

The 808-page report details systemic violations of financial regulations, weak internal controls, and unexplained payments made under controversial contracts.

The S&P 500 SPX has risen 14.5% this year through Friday. All price changes in this article exclude dividends. Through Friday, 57% of stocks in the S&P 500 were up for 2025.